Adenocarcinoma of Unknown Primary
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma which has metastasized from an unknown primary anatomic site. 
Adenocarcinoma of unknown primarys most frequently harbor alterations in TP53, KRAS, CDKN2A, SMAD4, and ARID1A .
TP53 Mutation, KRAS Mutation, KRAS Exon 2 Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in adenocarcinoma of unknown primary .
There are 4 clinical trials for adenocarcinoma of unknown primary, of which 3 are open and 1 is completed or closed. Of the trials that contain adenocarcinoma of unknown primary as an inclusion criterion, 2 are phase 1 (1 open) and 2 are phase 2 (2 open).
AR is the most frequent gene inclusion criterion for adenocarcinoma of unknown primary clinical trials .
Pc regimen, aldesleukin, and autologous natural killer cell-like ctls are the most common interventions in adenocarcinoma of unknown primary clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.